← Back to all trials
Not Yet Recruiting
NCT05720559
Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection
Conditions: Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
Sex: All
Ages: 18 Years – 80 Years
Phase: PHASE2
Enrollment: 100
Sponsor: Liaoning Tumor Hospital & Institute
Summary
In this study, the Quintuple method was applied for early intervention of prehepatic CTC-positive bowel cancer patients without dominant liver metastasis, aiming to explore the blocking effect of the Quintuple method on the metachronous liver metastases of colorectal cancer.
A one-arm randomized clinical trial was conducted, and the patients were grouped according to their treatment methods.
The patients with metachronous liver metastases were used as the end point of the experiment to evaluate the blocking effect of quintuple therapy.
Eligibility Criteria
Inclusion Criteria:Ages 18-80 at the time of signing the informed consent;Histologically or cytologically confirmed adenocarcinoma of the colon or rectum;Radical surgery has been performed;Imaging examination showed no liver metastasis;Prehepatic CTC number ≥1;The ECOG performance status is 0-1.No combination of other life-threatening diseases;Willingness and ability to follow scheduled visits, treatment plans, laboratory tests and other research procedures.Exclusion Criteria:Patients with non-primary colorectal cancer;Patients with liver metastasis or other organ metastasis;Patients without prehepatic CTC or whose prehepatic CTC were negative;People who are severely allergic to one or more of the drugs required in the test;Patients with severe underlying diseases of respiratory, circulatory, urinary and hematopoietic systems.
Source: ClinicalTrials.gov (NCT05720559). StuddyBuddy aggregates publicly available trial information.